Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Predictive Oncology Inc. POAI

Predictive Oncology Inc.’s (NASDAQ: POAI) AI Solutions to Combat Cancer, Similar Technological Solutions Called Upon to Fight COVID-19

Posted on March 17, 2020 by MissionIR

Artificial intelligence (AI) at forefront of scientific discovery, proving importance in fighting complex diseases Science turns to AI as effective tool to help find COVID-19 vaccines and therapeutics Predictive Oncology harnesses power of AI to improve cancer patient outcomes With … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Enters Securities Purchase Agreement to Raise $3.5M through Private Placement

Posted on March 16, 2020 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, this morning announced its entrance into a securities purchase agreement with certain accredited investors to raise $3.5 million through the issuance … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

Predictive Oncology Inc. (NASDAQ: POAI) AI/ML Expertise, Recent Acquisition Invaluable Resources in Search for New Anti-Virals, Vaccines

Posted on March 13, 2020 by MissionIR

POAI positioned as leader in using data, artificial intelligence in search for novel effective treatments Planned acquisition provides Predictive Oncology with CoRE(TM), a proven machine-learning framework Uniting CoRE with proprietary PDx tumor-profiling platform and tumor-data database creates one-of-a-kind, end-to-end “discovery … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Launch of New AI Platform for Vaccine and Drug Development Targeting COVID-19, MERS and SARS

Posted on March 12, 2020 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its plans to launch a new AI platform for vaccine and drug development targeting Coronaviruses and Acute Respiratory Syndromes … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

Predictive Oncology Inc. (NASDAQ: POAI) Signs LOI for Acquisition of Leading Biomedical Analytics Company, Novel Drug-Discovery Platform

Posted on March 5, 2020 by MissionIR

POAI’s planned acquisition of Quantitative Medicine (QM) will revolutionize the way precision therapies are developed QM’s CoRE platform predicts main effects of drugs on target molecules that mediate disease Synergies created by acquisition support POAI’s efforts to accelerate the commercialization … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

Predictive Oncology Inc.’s (NASDAQ: POAI) Key Focus Areas of Precision Medicine, AI Listed as Top Industry Investment Trends

Posted on March 4, 2020 by MissionIR

Precision medicine, AI among top healthcare investment trends for 2020 Predictive Oncology is data, AI-driven precision medicine company with an exclusive database of patient samples Market estimates for precision medicine expected to reach $84.6 billion by 2024 Precision medicine and … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Proposed Acquisition Further Positions it to Aid Efforts to Accelerate Discovery of New Anti-Cancers, Anti-Virals and Vaccines

Posted on March 2, 2020 by MissionIR

Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today provided an update on its proposed acquisition of Carnegie Mellon University … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Employs Unique Cancer-Research Approach

Posted on February 26, 2020 by MissionIR

Predictive Oncology’s (NASDAQ: POAI) flagship subsidiary TumorGenesis is making strides in the identification and separation of cancer-related biomarkers in an effort to quicken the development of new, effective therapeutics. TumorGenesis is currently utilizing a new trend in cancer research that … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Selects Manufacturer, Distributor of Innovative Cell-Culture Media

Posted on February 24, 2020 by MissionIR

POAI subsidiary announces new media for growing ovarian tumors in lab Using new product, TumorGenesis partners have identified 25 cell types from ovarian cancers New media available as cell-culture market expected to reach $2.3 billion by 2024 Predictive Oncology Inc. … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Another Exemplary Addition to its Board

Posted on February 21, 2020 by MissionIR

Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced that its Board of Directors has unanimously appointed Dan Handley, … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment